Want to join the conversation?
$AGN said it has received a Positive Opinion from the Swedish Medical Products Agency for BELKYRA. BELKYRA will be the first prescription medicine to be licensed in Europe for the treatment of moderate to severe convexity or fullness associated with submental fat (SF) in adults when the presence of SF has a psychological impact for the patients.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.